Motif Bio PLC said that it would be delaying the submission of a new drug application with the U.S. Food and Drug Administration for the approval of its antibiotic iclaprim.

The New-York-based biopharmaceutical company now plans to submit an application for iclaprim to treat acute bacterial skin and skin structure infections during the second quarter of 2018.

Motif Bio, which had planned to submit the application this quarter, said it was taking additional time to strengthen its filing.